[IL-6 targetting therapy for inflammatory immune diseases].
Nishimoto
Norihiro
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000209:etiology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology*; D005871:Castleman Disease / Q000188:drug therapy* / Q000209:etiology*; D002986:Clinical Trials as Topic; D006801:Humans; D018836:Inflammation Mediators; D015850:Interleukin-6 / Q000502:physiology*; D019947:Receptors, Interleukin-6 / Q000276:immunology; D015398:Signal Transduction; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018836:Inflammation Mediators; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab